Table 5. In vivo antileishmanial activity against L. donovani in a golden hamster model.

Compd. no	Percentage inhibition		Route of administration	Dose mg kg–1
	7th day	28th day
1h	36.0 ± 8.48	NI	IP	50
1k	39.5 ± 0.70	29.0 ± 0.0	IP	50
1m	36.0 ± 20.20	71.25 ± 10.56	IP	50
1m	48.41 ± 11.44	66.03 ± 8.74	Oral	100
4bb	44.02 ± 12.63	75.20 ± 6.64	IP	50
4kd	29.22 ± 41.32	NI	IP	50
4kk	50.92 ± 8.48	38.04 ± 2.6	IP	50
4md	13.51 ± 0.6	2.08 ± 3.6	IP	50
4mf	71.08 ± 11.11	28.63 ± 11.04	IP	50
4mf	69.47 ± 8.34	12.70 ± 8.91	Oral	100
6ba	NI	NI	IP	50
6gc	NI	NI	IP	50
6ka	19.32 ± 3.06	NI	IP	50
6kb	61.99 ± 2.46	9.23 ± 6.12	IP	50
6mc	20.01 ± 8.22	4.38 ± 5.28	IP	50
Miltefosine	97.32 ± 0.55	98.41 ± 1.41	Oral	30